Biopharmaceutical company Akeso Inc (HK:9926) announced on Friday that results from its randomised, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented at the 2026 European Hematology Association (EHA) Congress.

Ligufalimab is Akeso's proprietary next-generation humanised IgG4 anti-CD47 monoclonal antibody.

The study evaluated ligufalimab in combination with azacitidine (AZA) and venetoclax (VEN) in patients with treatment-naive acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. The abstract data demonstrated that the ligufalimab-based triplet regimen delivered encouraging efficacy, with significant improvements in survival outcomes. The combination also showed a manageable safety profile, offering a potentially better-tolerated treatment option for this vulnerable patient population.

Ligufalimab has already received Orphan Drug Designation (ODD) from the US FDA for the treatment of AML.